Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B (B-YOND)

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: August 19, 2011
Last updated: June 18, 2015
Last verified: October 2014

The primary objective of the study is to evaluate the long-term safety of rFIXFc in participants with hemophillia B.

The secondary objective of this study is to evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding episodes.

Condition Intervention Phase
Severe Hemophilia B
Biological: rFIXFc
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • Frequency of inhibitor development [ Time Frame: up to four years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The number of annualized bleeding episodes (spontaneous and traumatic) per participant [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • The number of annualized spontaneous joint bleeding episodes per participant [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • The total number of days of exposure per participant per year [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • The mean dose of rFIXFc per kg per participant per year per treatment regimen [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • Physicians global assessment of response to treatment using a 4-point scale [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • Participant's assessment of response to treatment using a 4-point scale [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • The incidence of AEs and serious adverse events (SAEs) [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
  • Investigator/Surgeon assessment of hemostatic response to surgery using the 4-point bleeding response scale [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • Number of injections and dose per injection to maintain hemostatis during the surgical period [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • Estimated blood loss (mL) during surgery and post-operative period [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
  • Number of blood product units transfused during surgery [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: December 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: On-Demand
Biological: rFIXFc
IV Administration
Other Names:
  • BIIB029
  • Alprolix
Experimental: Prophylaxis
Biological: rFIXFc
IV Administration
Other Names:
  • BIIB029
  • Alprolix

Detailed Description:

Participants will follow either a prophylaxis or on-demand regimen. The starting dose in this study will be determined by the clinical profile of the patient in the preceding studies, B-LONG 998HB102 (NCT01027364) and pediatric study 9HB02PED (NCT01440946)


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

Subjects who have completed previous rFIXFc studies (NCT01027364 and NCT01440946) Ability to understand the purposes & risks of the study and provide signed and dated informed consent.

Key Exclusion Criteria:

Confirmed positive high-titer inhibitor test (>/=5.00 BU/mL)

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01425723

  Show 46 Study Locations
Sponsors and Collaborators
Study Director: Medical Director Biogen
  More Information

No publications provided

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT01425723     History of Changes
Other Study ID Numbers: 9HB01EXT, 2011-003075-11
Study First Received: August 19, 2011
Last Updated: June 18, 2015
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Ireland: Irish Medicines Board
China: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
India: Ministry of Health
Hong Kong: Department of Health
Italy: Ministry of Health
South Africa: Department of Health
Japan: Pharmaceuticals and Medical Devices Agency (PMDA)
Brazil: Ministry of Health
Sweden: Medical Products Agency
Germany: Federal Institute for Drugs and Medical Devices
Canada: Health Canada
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
United States: Food and Drug Administration

Keywords provided by Biogen:
B-LONG Extension
Severe Hemophilia B

Additional relevant MeSH terms:
Hemophilia B
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Hematologic Diseases
Hemorrhagic Disorders

ClinicalTrials.gov processed this record on June 28, 2015